ライフサイエンスコーパス: phospholipase

1 ting imbalanced Lands' cycle by knockdown of phospholipase 2 (cPLA2) or overexpression of lysophospha

2 TT>deltaG, rs12979860 C>T, and patatin-like phospholipase-3 rs738409 C>G polymorphisms were genotype

3 In Gram-negative bacteria, outer membrane phospholipase A (OmpLA) is involved in outer-membrane li

4 tinized the unfolded state of outer-membrane phospholipase A (OmpLA) to provide a detailed view of it

5 chniques, we discover that ACT has intrinsic phospholipase A (PLA) activity, and that such activity d

6 es an essential enzyme with thioesterase and phospholipase A activity.

7 for phosphatidyl-based substrate binding and phospholipase A activity.

8 d that the dominant mlaA* mutation activates phospholipase A, resulting in increased levels of lipopo

9 f genes encoding 13-lipoxygenases (LOXs) and phospholipase A-Igamma3 (At1g51440), a plastid lipase wi

10 er phosphodiesterases and three patatin-like phospholipases A on the transcriptome level.

11 proteins, which belong to the intracellular phospholipase A1 (iPLA1) family, have been predicted to

12 (WDCL) and enzymatic degumming (EDCL) using phospholipase A1 (PLA1).

13 PLIP1 is a phospholipase A1 In vivo, PLIP1 hydrolyzes polyunsaturat

14 and no PA production could be detected using phospholipase A1, phospholipase A2, or phospholipase C,

15 doxin 6 (Prdx6), a bifunctional protein with phospholipase A2 (aiPLA2) and GSH peroxidase activities,

16 DX6 or inhibition of its calcium-independent phospholipase A2 (Ca(2+)-iPLA2) activity by MJ33 on fert

17 ls of MYC, we found an increase in cytosolic phospholipase A2 (cPLA2) activity with a preferential re

18 Tissue damage activates cytosolic phospholipase A2 (cPLA2), releasing arachidonic acid (AA

19 tease-activated receptors 1 and 4, cytosolic phospholipase A2 (cPLA2), Src tyrosine kinases, p38 MAPK

20 acid by phospholipase A2, and the cytosolic phospholipase A2 (cPLA2)alpha isoform has been specifica

21 Group IVA cytosolic phospholipase A2 (cPLA2alpha) acts as a bridge in this c

22 Cytosolic phospholipase A2 (GIVA cPLA2) is the only PLA2 that exhi

23 Activation of group VIA phospholipase A2 (iPLA2beta) causes accumulation of arac

24 vated levels of human lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with cardiovas

25 Lipoprotein-associated phospholipase A2 (Lp-PLA2) hydrolyses oxidized low-densi

26 iated with changes in lipoprotein-associated phospholipase A2 (n = 10; r = 0.67; P = .03).

27 Phospholipase A2 (PLA)-specific B cells were identified

28 Phospholipase A2 (PLA2) activity has been shown to be in

29 ybean seeds and positively characterised for phospholipase A2 (PLA2) activity, suggesting their plaus

30 Here, we propose that 2 enzymes-phospholipase A2 (PLA2) and ectonucleotide pyrophophatas

31 In both plants, an elicitor-responsive phospholipase A2 (PLA2) at the plasma membrane generates

32 the demonstration that lipid enzymes such as phospholipase A2 (PLA2) contain allosteric activator sit

33 In addition, phospholipase A2 (PLA2) is highly expressed in psoriatic

34 The development of inhibitors for phospholipase A2 (PLA2) is important in elucidating the

35 n after lung challenge with S. pneumoniae As phospholipase A2 (PLA2) promotes the release of AA, we i

36 of cancer cells was critically dependent on phospholipase A2 (PLA2) to mobilize lysophospholipids an

37 le of sequestering and neutralizing venomous phospholipase A2 (PLA2), we demonstrate that broad-spect

38 hate (cAMP) and a subsequent inactivation of phospholipase A2 (PLA2), whose metabolites are known to

39 Phospholipase A2 (PLA2)-dependent pathways are important

40 Among snakes, phospholipase A2 (PLA2)-related toxins have evolved in d

41 ), two in apolipoprotein B (APOB) and one in phospholipase A2 (PLA2G4A) that significantly associated

42 l. (2017) provide intriguing evidence that a phospholipase A2 (Pla2gb1) produced by epithelial cells

43 ays, we found expression levels of secretory phospholipase A2 (sPLA2), lysophospholipid acyltransfera

44 tional screen, we have identified a secreted phospholipase A2 (sPLA2)-like protein, BomoTx, from the

45 strong upregulation of the secreted group V phospholipase A2 (sPLA2-V), both at the mRNA and protein

46 Group IVA phospholipase A2 [cytosolic phospholipase A2alpha (cPLA2

47 induced [Formula: see text] signals required phospholipase A2 activation.

48 se cleavages disrupt both the peroxidase and phospholipase A2 activities of Prdx6.

49 l or Prdx6-D140A-knock-in mice that lack the phospholipase A2 activity (PLA2) of Prdx6; addition of e

50 easurement of prostaglandin E2 and cytosolic phospholipase A2 activity in membrane fractions of fibro

51 The phospholipase A2 activity of peroxiredoxin 6 modulates N

52 Treatment with PEDF activates the phospholipase A2 activity of the PEDF-receptor (PEDF-R)

53 onses are elicited through lipid products of phospholipase A2 activity that acts on the membrane phos

54 hospholipases, which have been shown to have phospholipase A2 activity.

55 r levels of hsCRP and lipoprotein-associated phospholipase A2 after AMI compared with men, and this r

56 2+) release from internal stores, activating phospholipase A2 and generating vasodilatory arachidonic

57 hetic enzymes includes (1) the activation of phospholipase A2 at the plasma membrane, resulting in a

58 urons caused the dissociation of cytoplasmic phospholipase A2 from PrP-containing membrane rafts and

59 Here we identify epithelial-cell-derived phospholipase A2 group 1B (PLA2g1B) as a host-derived en

60 04, n >/=5/group) for five other NBIA genes, phospholipase A2 group VI, fatty acid 2-hydroxylase, cer

61 esterol, adiponectin, lipoprotein-associated phospholipase A2 mass and activity, monocyte chemoattrac

62 The phospholipase A2 receptor (PLA2R) and thrombospondin typ

63 Phospholipase A2 receptor (PLA2R) is a member of the man

64 pathy (IMN) have IgG4 autoantibodies against phospholipase A2 receptor (PLA2R).

65 The phospholipase A2 receptor (PLA2R1) is the major autoanti

66 The phospholipase A2 receptor (PLA2R1) is the major autoanti

67 le is known about the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein

68 tly discovered podocyte antigens: the M-type phospholipase A2 receptor 1 (PLA2R) and thrombospondin t

69 bodies against the podocyte surface antigens phospholipase A2 receptor 1 (PLA2R1) and the recently id

70 ephropathy (MN) along with the major antigen phospholipase A2 receptor 1 (PLA2R1).

71 e ExoU type III secretion enzyme is a potent phospholipase A2 secreted by the Gram-negative opportuni

72 ity to induce prostaglandin E2 and cytosolic phospholipase A2 synthesis in patients' fibroblasts.

73 d a novel cardiolipin hydrolysis reaction by phospholipase A2 to form diacylated cardiolipin progress

74 e protein (hsCRP) and lipoprotein-associated phospholipase A2 were measured 1 month after AMI.

75 crophages, activation of group IVA cytosolic phospholipase A2(cPLA2alpha) by calcium- and mitogen-act

76 serum amyloid protein A), NPS-PLA2 (secreted phospholipase A2), and CA6 (carbonic anhydrase 6).

77 ry enzymes (ciclooxygenase, lipoxygenase and phospholipase A2).

78 Tgm2, group 10 secretory phospholipase A2, and LT enzymes in NHBEs and nasal poly

79 ion is the liberation of arachidonic acid by phospholipase A2, and the cytosolic phospholipase A2 (cP

80 d on a denatured form of the major allergen, phospholipase A2, associated with microbubbles (PLA2dena

81 (COX-2)/prostaglandin E2 signaling cascade (phospholipase A2, COX-2, multidrug resistance protein 4,

82 on could be detected using phospholipase A1, phospholipase A2, or phospholipase C, allowing for a rel

83 yclooxygenase-2 and phosphorylated cytosolic phospholipase A2, which was reflected in prostaglandin E

84 adult mice expressed more group 10 secretory phospholipase A2, Wnt5a, and transglutaminase 2 (Tgm2).

85 evels of prostaglandin E2 The non-functional phospholipase A2-activating protein and the associated n

86 a loss of function sequence variation in the phospholipase A2-activating protein encoding gene (PLAA)

87 Phospholipase A2-specific IgG4-switched memory B cells e

88 ts and reduced the activation of cytoplasmic phospholipase A2.

89 ase D2 and diacylglycerol kinase rather than phospholipase A2.

90 PAF-AH2, an oxidized-phospholipid-selective phospholipase A2.

91 crosis factor-alpha, C-reactive protein, and phospholipase A2.

92 ipid as a novel substrate of honey bee venom phospholipase A2.

93 Phospholipase A2/5-lipoxygenase/leukotriene-B4 (PLA2/5-L

94 c activity of soluble lipoprotein-associated phospholipase A2; at CYP2F1, with higher plasma interleu

95 Cytosolic phospholipases A2 (cPLA2s) consist of a family of calciu

96 Here, we identify secreted phospholipases A2 (sPLA2s) as stem cell niche factors wi

97 Group IVA phospholipase A2 [cytosolic phospholipase A2alpha (cPLA2alpha)] is a key mediator of

98 Cytosolic phospholipase A2alpha, which mobilizes arachidonic acid

99 dependent upon calcium-independent group VIA phospholipase A2beta (iPLA2beta) following infection of

100 ding to the activation of Ca(2+)-independent phospholipase A2gamma (iPLA2gamma) and the production of

101 Calcium-independent phospholipase A2gamma (iPLA2gamma) is a mitochondrial en

102 reported previously that calcium-independent phospholipase A2gamma (iPLA2gamma) is cytoprotective aga

103 yl chains from CL by the calcium-independent phospholipase A2gamma (iPLA2gamma)-selective inhibitor (

104 Phospholipase A2s mediate the rate-limiting step in the

105 rom non-failing hearts was calcium-dependent phospholipase A2zeta (cPLA2zeta) identified by sequentia

106 (PRMT8) possesses both methyltransferase and phospholipase activities.

107 e truncated ExoU proteins partially restored phospholipase activity and cytotoxicity, indicating that

108 thogen, Pseudomonas aeruginosa Activation of phospholipase activity is induced by protein-protein int

109 anism by which this coactivator enhances the phospholipase activity of ExoU.

110 e data indicate that cPLA2alpha, through its phospholipase activity, is a critical effector of G1 pha

111 mology, and Ras-associating domains, but not phospholipase activity, to this pathway.

112 lipid bilayer without revealing any signs of phospholipase activity.

113 cpla2alphaa and cpla2alphab, with conserved phospholipase activity.

114 As our understanding of phospholipases advanced, so did the understanding that m

115 While many pathogen-derived phospholipases also manipulate the immune response, they

116 Lpl1 is a phospholipase and a component of the lipid droplet.

117 ccelerated DHA catabolism (eg, activation of phospholipases and oxidation pathways) could explain the

118 tion in MATRILINEAL (MTL), a pollen-specific phospholipase, and that novel edits in MTL lead to a 6.7

119 Phospholipases are abundant in various types of cells an

120 Parasite-derived patatin-like phospholipases are likely effective drug targets and pro

121 FN1704) that we hereby rename Fusobacterium phospholipase autotransporter (FplA).

122 thuringiensis phosphatidylinositol-specific phospholipase C (BtPI-PLC) is a secreted virulence facto

123 The activation of phosphoinositide-specific phospholipase C (PI-PLC) is one of the earliest response

124 are incubated with phosphoinositide-specific phospholipase C (PI-PLC).

125 endogenous PIP2 either by serotonin-induced phospholipase C (PLC) activation or by a rapamycin-induc

126 ling cascade culminating in phosphoinositide-phospholipase C (PLC) activation, which generates the se

127 el inhibition by depletion of PI(4,5)P2 upon phospholipase C (PLC) activation.

128 1,4,5 trisphosphate (IP3 ) accumulation and phospholipase C (PLC) activity were significantly potent

129 signaling pathway mediated by G proteins and phospholipase C (PLC) beta1.

130 Ca(2+) -induced activation of phospholipase C (PLC) has been implied in the regulation

131 by astrocytes is prevented by BAPTA-AM or a phospholipase C (PLC) inhibitor.

132 tors and receptor tyrosine kinases, activate phospholipase C (PLC) isozymes to hydrolyze phosphatidyl

133 the G-protein-coupled receptor (GPCR)-Gq/11-phospholipase C (PLC) pathway.

134 channels TRPC4 and -5 via the Gq/11 protein-phospholipase C (PLC) signaling pathway has remained elu

135 we used on-tissue treatment with buffer-free phospholipase C (PLC) to near-quantitatively degrade PCs

136 Inhibition of phospholipase C (PLC) with U73122 did not inhibit either

137 boundary as merely a substrate for PI3K and phospholipase C (PLC), and is now an established lipid m

138 (NAPE-PLD), diacylglycerol lipase (DAGL), or phospholipase C (PLC), and their metabolism is mediated

139 PM8) channels are thought to be regulated by phospholipase C (PLC), but neither the specific PLC isof

140 the fibroblast growth factor (FGF) receptor, phospholipase C (PLC), protein kinase C (PKC) and phosph

141 inds its two major classes of effectors, the phospholipase C (PLC)-beta isozymes and Rho guanine nucl

142 ownstream from receptors that signal through phospholipase C (PLC).

143 requires G protein alpha q subunit (Galphaq)/phospholipase C (PLC)beta1 activities and protein kinase

144 requires G protein alpha q subunit (Galphaq)/phospholipase C (PLC)beta1/protein kinase C (PKC) activi

145 itment of TRPC3 or phosphoinositide-specific phospholipase C (PLCgamma) to the AT1R-beta-arrestin-1 s

146 A sperm-specific phospholipase C (PLCZ1) has emerged as the likely candid

147 tly enhanced bone formation, indicating that phospholipase C activation is not required for increased

148 Restoration of PI(4,5)P2 levels after phospholipase C activation is therefore essential for a

149 erstand dynamic effects of receptor-mediated phospholipase C activation on excitability and other PI(

150 from intracellular stores via activation of phospholipase C and opening of inositol trisphosphate (I

151 se embryo at the 8-cell stage is directed by Phospholipase C and Protein kinase C and occurs in two p

152 eved either by agonist-induced activation of phospholipase C beta or with a rapamycin-inducible syste

153 lated HUVEC migration and proliferation in a phospholipase C beta-dependent fashion and decreased Gal

154 effect of NAC on Galphaq palmitoylation and phospholipase C beta-mediated signaling in endothelial c

155 strate 1 (Rac1)-dependent activation of both phospholipase C beta2 (Plcbeta2) and Plcbeta3.

156 ronchial aSMCs, through its association with phospholipase C beta2 and the stimulation of inositol 1,

157 ng components (i.e., G-protein gustducin and phospholipase C beta2).

158 correlated with an association of PP1c with phospholipase C beta3 (PLCbeta3), along with a concomita

159 /11 heterotrimeric G proteins, and in PLCB4 (phospholipase C beta4), the downstream effector of Galph

160 sphate counteracted the direct activation of phospholipase C by 2,4,6-trimethyl-N-[3-(trifluoromethyl

161 ed by cAMP (Epac) provokes inhibition of the phospholipase C by an as yet unknown mechanism.

162 ition by the default PI(4,5)P2 lipid sensor, phospholipase C delta 1 pleckstrin homology domain (PLC

163 r activation of T cells (LAT), and activated phospholipase C gamma 1 (PLCgamma1), which all localize

164 ernal GDP-beta-S or inhibiting OX1Rs, CB1Rs, phospholipase C or DAGL, and potentiated by inhibiting 2

165 protein expression of MMPs and RANKL via the phospholipase C pathway.

166 of stimulation with agonists that engage the phospholipase C pathway.

167 phatidylinositol-specific phospholipase C, a phospholipase C specific for the cleavage of glycosylpho

168 cerophosphodiesterase GDE3 as a GPI-specific phospholipase C that cleaves and releases uPAR with cons

169 ion of cell-surface receptors that couple to phospholipase C to generate the second messenger inosito

170 itol (PI) by targeting bacterial PI-specific phospholipase C to the PIS domain impairs recruitment of

171 d protein kinase A (PKA) via Gsalpha but not phospholipase C via Gq/11 (D/D mice), PTH significantly

172 yte at fertilisation, a process initiated by phospholipase C zeta (PLCzeta), a sperm-specific protein

173 cytoplasmic sperm injection or expression of phospholipase C zeta.

174 -2-decanoylamino-3-morpholino-1-propanol and phospholipase C), we demonstrated that PSV could recogni

175 treatment with phosphatidylinositol-specific phospholipase C, a phospholipase C specific for the clea

176 using phospholipase A1, phospholipase A2, or phospholipase C, allowing for a reliable determination o

177 A2 (cPLA2), Src tyrosine kinases, p38 MAPK, phospholipase C, and intracellular calcium.

178 Galphaq, on the other hand, signals through phospholipase C, and it remains unclear whether Galphaq-

179 1 metabotropic glutamate receptors, Homer2, phospholipase C, and/or phosphotidylinositide-3 kinase f

180 y due to the hydrolytic activity of Sac2 and phospholipase C, becoming undetectable for approximately

181 of the nerves requires the beta3 isoform of phospholipase C, but TRPA1 or other TRP channel are not

182 s involving a G-protein q, the activation of phospholipase C, calcium mobilization, and the release o

183 radicals, lipid peroxidation, activation of phospholipase C, IP3 receptors, and release of Ca(2+) fr

184 in Na/K-ATPase signaling, such as caveolin, phospholipase C, Src, and the IP3 receptor.

185 nistic studies indicate that EDNRA activates phospholipase C, which then 1) increases the MMP1 protei

186 Mammalian phospholipase C-beta (PLC-beta) isoforms are stimulated

187 gamma subunits, and some Rho family GTPases, phospholipase C-beta (PLC-beta) isoforms hydrolyze phosp

188 hototransduction pathway, which requires the phospholipase C-beta encoded by norpA (no receptor poten

189 iquitous activation of Ca(2+) signaling upon phospholipase C-coupled receptor ligation leads quite na

190 urons and generate 2-AG through a Gq-protein-phospholipase C-DAGL cascade.

191 CD40 ligation in Muller cells triggered phospholipase C-dependent ATP release that caused P2X7-d

192 to the membrane by diacylglycerol (DAG) in a phospholipase C-gamma (PLCgamma)-dependent manner.

193 In turn, H2O2 activates a Src kinase/phospholipase C-gamma1 (PLC-gamma1) signaling pathway an

194 c, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-gamma1 (PLCgamma1) have all been implica

195 Mutations in the gene encoding phospholipase C-gamma2 (PLCgamma2) have been shown to be

196 Depletion of PI(4,5)P2 via phospholipase C-mediated hydrolysis leads to a decrease

197 g a variety of approaches, we also show that phospholipase C-mediated PIP2 hydrolysis is necessary an

198 ctivation of G protein, protein kinase C and phospholipase C.

199 ons to cause uncoupling of H1 receptors from phospholipase C.

200 bition of Na(+)/H(+) exchange or blockade of phospholipase C.

201 lecular mechanism underlying this process: a phospholipase C/Ca(2+)/proline-rich tyrosine kinase 2/cJ

202 framework for a mechanistic understanding of phospholipase C/PKC signaling in chemotactic gradient se

203 op and analyze a reaction-diffusion model of phospholipase C/protein kinase C (PKC) signaling, which

204 e determinants of pathogenesis: two secreted phospholipases C (PLCs; PlcA and PlcB) and a surface pro

205 s includes the calmodulin inhibitor W-7, the phospholipase-C inhibitor U73122, and anti-psychotic phe

206 entiation (PTP) or through activation of the phospholipase-C-diacylglycerol pathway share characteris

207 e show that manipulation of the non-specific phospholipase C1, NPC1, alters silicon content in nodes

208 cellular levels of phosphoinositide-specific phospholipase Cbeta (PLCbeta) and its activator, Galphaq

209 Phospholipase Cbeta (PLCbeta) is activated by G protein

210 The second pathway activates phospholipase Cbeta and induces myosin light chain phosp

211 alcium signals generated through the Galphaq/phospholipase Cbeta signaling pathway and that subjectin

212 f Gq signaling and its downstream components phospholipase Cbeta, protein kinase Cepsilon, calcineuri

213 on potential discharge was largely absent in phospholipase Cbeta3 knockout animals.

214 -mediated interference screen, we identified phospholipase Cepsilon 1 (PLCepsilon1) as a crucial regu

215 rate that recruitment and phosphorylation of Phospholipase Cgamma (PLCgamma), a prototypical SH2 cont

216 deficiency did not affect phosphorylation of phospholipase Cgamma or Ca(2+) influx, it was associated

217 rosine kinase, spleen tyrosine kinase [SYK], phospholipase Cgamma), but had low alpha-BCR-induced sig

218 o interacts with the p85 subunit of PI3K and phospholipase Cgamma, enzymes that deplete plasma membra

219 t uniquely required to observe activation of phospholipase Cgamma.

220 Phospholipases Cgamma (PLCgamma) 1 and 2 are a class of

221 association between BD and the gene encoding phospholipase Cgamma1 (PLCG1), its etiological basis rem

222 Here, we report that mice lacking phospholipase Cgamma1 (PLCgamma1) in the forebrain (Plcg

223 Strong evidence suggests that phospholipase Cgamma1 (PLCgamma1) is a suitable target t

224 We find that perturbations of phospholipase Cgamma1 (PLCgamma1), Ca(2+), or protein ki

225 d by specific loss of TrkB signaling through phospholipase Cgamma1 (PLCgamma1).

226 F) could directly activate EGCs via the TrkB-phospholipase Cgamma1 pathway, thereby inducing a signif

227 omain (CID) and the Src homology 3 domain of phospholipase Cgamma1.

228 e Hck, Wiskott-Aldrich-syndrome protein, and phospholipase Cgamma2 were also involved in this pathway

229 ase)-Syk (spleen tyrosine kinase)-PLCgamma2 (phospholipase Cgamma2) pathway.

230 rylation of spleen tyrosine kinase (SYK) and phospholipase Cgamma2.

231 mediate targets Bruton's tyrosine kinase and phospholipase Cgamma2.

232 characterization of an F. nucleatum Type Vd phospholipase class A1 autotransporter (strain ATCC 2558

233 hat photoreceptors contain a light-dependent phospholipase D (PLD) activity.

234 ncreased activity of the PA-producing enzyme phospholipase D (PLD) and increased localization of PLD1

235 ) and MMP9, whereas the ED peptide activates phospholipase D (PLD) and MMP2, but not MMP9.

236 ther genes annotated as a helicase domain, a phospholipase D (PLD) domain, a DUF1998 domain and a gen

237 or imaging sites of cellular PA synthesis by phospholipase D (PLD) enzymes is reported.

238 gh its production of phosphatidic acid (PA), phospholipase D (PLD) is strongly involved in vesicular

239 Phospholipase D (PLD) proteins are enzymes that catalyze

240 The Phospholipase D (PLD) superfamily is linked to neurologi

241 feedback loop between the signaling protein phospholipase D (PLD), phosphatidic acid (PA), and a spe

242 DNase II exhibits a similar overall fold as phospholipase D (PLD), phosphatidylserine synthase (PSS)

243 RNAs (miRs) mediated by the signaling enzyme phospholipase D (PLD).

244 The effects of phospholipase D activity and its product phosphatidic ac

245 Both phospholipase D activity and vesicular trafficking were

246 modulators of development such as CDC48A and phospholipase D alpha 1.

247 rpretations concerning the possible roles of phospholipase D and its biologically active product phos

248 Venoms of the sicariid spiders contain phospholipase D enzyme toxins that can cause severe derm

249 s in chlamydial cytotoxins, guaBA-add, and a phospholipase D homolog developed normally in cell cultu

250 While using phospholipase D inhibitors (which block the conversion o

251 evidence that the plasma membrane localized phospholipase D, involved in the biosynthesis of PA, is

252 nd LEP localization in cells lacking Sma1, a phospholipase D-associated protein dispensable for initi

253 glycerol into PG and is catalyzed by ClsB, a phospholipase D-type cardiolipin synthase.

254 dered important in NAFLD, the involvement of phospholipase D1 (PLD1) has not yet been studied.

255 ally, elevated membrane tension acts through phospholipase D2 (PLD2) and the mammalian target of rapa

256 tments that inactivate the signalling enzyme phospholipase D2 (PLD2) by sequestering the enzyme from

257 We show that knockout of phospholipase D2 (PLD2), which generates the signaling l

258 d that Ca(2+) generates arachidonic acid via phospholipase D2 and diacylglycerol kinase rather than p

259 eveal that a signaling molecule generated by phospholipase D2 drives deposition of MT1-MMP at the sit

260 stream of ARF6 small GTPase and its effector phospholipase D2, directly phosphorylating the conserved

261 kalinization and are regulated by the enzyme phospholipase D2.

262 Phospholipase D4 (PLD4), a single-pass transmembrane gly

263 GS1) protein and a lipid-hydrolyzing enzyme, phospholipase Dalpha1 (PLDalpha1), both act as GTPase-ac

264 We now present evidence that the phospholipase Dalpha1 protein is a key component and mod

265 cid or prostaglandin E2 (PGE2), indicating a phospholipase-dependent mechanism.

266 membrane-embedded protein or as a truncated phospholipase domain that remains associated with the ou

267 Mutations in patatin-like phospholipase domain-containing 1 (PNPLA1) cause autosom

268 e genetic polymorphism I148M of patatin-like phospholipase domain-containing 3 (PNPLA3) is robustly a

269 isk variants of genes including patatin-like phospholipase domain-containing 3 and transmembrane 6 su

270 irectly activates expression of patatin-like phospholipase domain-containing enzyme 8 (PNPLA8) gene,

271 A sequence variation (I148M) in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is st

272 Neither patatin-like phospholipase domain-containing protein 3 rs738409 nor t

273 rized serine hydrolase (PNPLA4, patatin-like phospholipase domain-containing protein 4) involved in a

274 Proteins containing patatin-like phospholipase domains have been identified in protozoan

275 In this study, two Arabidopsis phospholipase Dzeta genes (AtPLDzeta1 and AtPLDzeta2 ) w

276 tyrosine 783 (Y783) leading to activation of phospholipase function and subsequent production of the

277 n Grb2, src-kinase Lyn and signal transducer phospholipase gamma2 (PLC-gamma2), and increased activat

278 es (SFKs), spleen tyrosine kinase (Syk), and phospholipase gamma2 (PLCgamma2).

279 trated with the results against autotaxin, a phospholipase implicated in cardiovascular disease.

280 thological remodeling of human mitochondrial phospholipases in failing myocardium.

281 nd characterize the role of Type Vd secreted phospholipases in Gram-negative bacteria.

282 researchers to dissect the complex roles of phospholipases in lipid metabolism, cellular signaling a

283 These results point to RcsPLA2alpha as a phospholipase involved in acyl editing, adapted to speci

284 ng activity of H2O2; and was able to inhibit phospholipase, lipoxygenase and cyclooxygenase, three pr

285 Moreover, a PA-producing phospholipase, MitoPLD, binds Drp1, creating a PA-rich m

286 ivated by SEB with or without inhibitors for phospholipases (PL) (-C or -D), or cycloheximide, or bre

287 ory lipid metabolism, free arachidonic acid, phospholipases (PLA2G10), and prostaglandin synthesis-re

288 n and wound closure by activating a Wnt-like phospholipase (PLC)/ protein kinase C (PKC) signaling ca

289 al virulence genes (Listeriolysin O, and two phospholipases plcA and plcB) in a concentration-depende

290 factor receptor-bound protein (Grb2) and the phospholipase Plcgamma1 compete for the same binding sit

291 Host phospholipase products are involved in stimulating and r

292 ExoU is a patatin-like A2 phospholipase requiring the cellular host factors phosph

293 Remarkably, the major mitochondrial phospholipase responsible for Ca(2+)-activated release o

294 Overexpression of a phospholipase TgLCAT, which is localized to the IVN, res

295 t mediates actin-based motility, and PlcB, a phospholipase that mediates vacuole escape.

296 activates specific myocardial mitochondrial phospholipases that increase Ca(2+)-dependent production

297 acids (HETEs) and attenuate the activity of phospholipases that promote the synthesis of protective

298 vated clearance pathway and recruitment of a phospholipase to enable genome release.

299 xplanation for the targeting of patatin-like phospholipases to the plasma membrane and define the MLD

300 y pathogens contain a family of patatin-like phospholipases, which have been shown to have phospholip